Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease
Daniel Boulos, Gene-Siew Ngian, Anton Rajadurai, Kathleen Elford, Wendy Stevens, Susanna Proudman, Claire Owen, Janet Roddy, Mandana Nikpour, Peter Youssef, Catherine Hill, Joanne Sahhar
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | WILEY | Published : 2017
OBJECTIVES: To assess the long-term efficacy and tolerability of mycophenolate mofetil (MMF) in patients with diffuse cutaneous systemic sclerosis (dcSSc). METHODS: Patients enrolled in the Australian Scleroderma Cohort study with dcSSc and baseline modified Rodnan skin score (mRSS) ≥ 12 who were treated for a minimum of 12 months with MMF for the primary indication of skin disease were included and their prospectively collected data retrieved. Change in mRSS, the proportion with a clinically significant improvement (reduction in mRSS ≥ 5 from baseline) and adverse effects due to therapy were determined. RESULTS: Seventy-four participants treated with MMF were identified and of these, 42 met..View full abstract
Related Projects (1)
The Australian Scleroderma Cohort Study is managed by the Australian Scleroderma Interest Group and supported by the St Vincent's Hospital IT Department and Research Endowment Foundation, Scleroderma Australia, Arthritis Australia and unrestricted educational grants from Actelion Australia, GSK and Pfizer.